Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

Researchers assessed survival outcomes for Asian patients with newly diagnosed AML vs White patients. Researchers determined Asian patients with newly diagnosed AML may have superior OS outcomes ...

Patients with RRMM with renal impairment demonstrated similar efficacy and safety outcomes with talquetamab as those without renal impairment.

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL. Combination odronextamab plus CHOP had promising response rates with a ...

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Adding tucatinib to first-line maintenance therapy with trastuzumab/pertuzumab extends PFS for patients with previously-treated HER2+ metastatic breast cancer.

Pooled data from 3 phase III clinical trial shows that the addition of neoadjuvant carboplatin to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer.

In patients with triple-negative breast cancer who have received neoadjuvant chemotherapy, testing for Ki67 and TILs has prognostic value.

Investigators sought to identify a relationship between cruciferous vegetable intake and breast cancer risk in the Nurses’ Health Study (NHS) and NHSII.

Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.